Cargando…
Better survival of renal cell carcinoma in patients with inflammatory bowel disease
BACKGROUND: Immunosuppressive therapy may impact cancer risk in inflammatory bowel disease (IBD). Cancer specific data regarding risk and outcome are scarce and data for renal cell carcinoma (RCC) are lacking. We aimed(1) to identify risk factors for RCC development in IBD patients (2) to compare RC...
Autores principales: | Derikx, Lauranne A.A.P., Nissen, Loes H.C., Drenth, Joost P.H., van Herpen, Carla M., Kievit, Wietske, Verhoeven, Rob H.A., Mulders, Peter F.A., Hulsbergen-van de Kaa, Christina A., Boers-Sonderen, Marye J., van den Heuvel, Tim R.A., Pierik, Marieke, Nagtegaal, Iris D., Hoentjen, Frank |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742003/ https://www.ncbi.nlm.nih.gov/pubmed/26447542 |
Ejemplares similares
-
Long-term Risk of Advanced Neoplasia After Colonic Low-grade Dysplasia in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study
por: De Jong, Michiel E, et al.
Publicado: (2019) -
Laryngeal Carcinoma in Patients With Inflammatory Bowel Disease: Clinical Outcomes and Risk Factors
por: van de Ven, Steffi E M, et al.
Publicado: (2020) -
Clonal Patterns Between Pouch Neoplasia and Prior Colorectal Neoplasia in Inflammatory Bowel Disease Patients: An Exploratory Cohort Study
por: te Groen, Maarten, et al.
Publicado: (2023) -
Increased Colorectal Neoplasia Risk in Patients with Inflammatory Bowel Disease and Serrated Polyps with Dysplasia
por: de Jong, Michiel E., et al.
Publicado: (2022) -
Long-Term Clinical Outcomes After Switching from Remicade(®) to Biosimilar CT-P13 in Inflammatory Bowel Disease
por: Smits, Lisa J. T., et al.
Publicado: (2017)